Press Releases Events & Presentations Event Details Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Apr 17 - Apr 21, 2026 Supporting Materials Virologic Analyses Following Treatment With ABI-5366, a Novel, Oral, Long-Acting HSV Helicase Primase Inhibitor in Participants Seropositive With Recurrent Genital Herpes 564.9 KB The Safety and Tolerability of ABI-5366, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor in Participants With Recurrent Genital Herpes 562.6 KB Shareholder Tools Print Email Alerts RSS News Feeds Search Investors
Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Apr 17 - Apr 21, 2026 Supporting Materials Virologic Analyses Following Treatment With ABI-5366, a Novel, Oral, Long-Acting HSV Helicase Primase Inhibitor in Participants Seropositive With Recurrent Genital Herpes 564.9 KB The Safety and Tolerability of ABI-5366, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor in Participants With Recurrent Genital Herpes 562.6 KB
Virologic Analyses Following Treatment With ABI-5366, a Novel, Oral, Long-Acting HSV Helicase Primase Inhibitor in Participants Seropositive With Recurrent Genital Herpes 564.9 KB
The Safety and Tolerability of ABI-5366, a Novel, Oral, Long-Acting HSV Helicase-Primase Inhibitor in Participants With Recurrent Genital Herpes 562.6 KB
